Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.69 |
| ▸ | CXCR3 | P49682 | 11/20 | 0.67 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18729961 | 1.00 | TMEM97 (0.69) | TMEM97SIGMAR1CXCR3PDK1PDK2 | |
| SCHEMBL17114684 | 0.88 | TMEM97 (0.80) | TMEM97SIGMAR1CXCR3PTGDR2 | |
| SCHEMBL17114887 | 0.87 | CXCR3 (0.65) | TMEM97SIGMAR1CXCR3PDK1PDK2 | |
| SCHEMBL17114884 | 0.87 | CXCR3 (0.65) | TMEM97SIGMAR1CXCR3PDK1PDK2 | |
| SCHEMBL17114910 | 0.86 | CXCR3 (0.53) | TMEM97SIGMAR1CXCR3PDK1PDK2 | |
| SCHEMBL17114908 | 0.86 | CXCR3 (0.53) | TMEM97SIGMAR1CXCR3PDK1PDK2 | |
| SCHEMBL18730093 | 0.85 | CXCR3 (0.67) | TMEM97SIGMAR1CXCR3PDK1PDK2 | |
| SCHEMBL18730091 | 0.85 | CXCR3 (0.67) | TMEM97SIGMAR1CXCR3PDK1PDK2 | |
| SCHEMBL19521562 | 0.82 | TMEM97 (1.00) | TMEM97SIGMAR1CXCR3PTGDR2 | |
| SCHEMBL18730129 | 0.82 | CXCR3 (0.81) | TMEM97SIGMAR1CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122741-B1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-06-06 | — | — | EP | disclosed |
| US-9951063-B2 | 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | CXCR3, CXCR1, CXCR2 | TMEM97 367/4885SIGMAR1 211/4885CXCR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.